Table 1.

Summary of tissue samples from patients with lung adenocarcinoma with EGFR-activating mutations

PatientSpecimenTypeBOREGFR mutationT790MMET amplificationHGFMET
Intrinsic resistancePretreatment specimens
1Pre-gefitinibPrimary lung cancerPDL858RNNHigh2+
2Pre-gefitinibPrimary lung cancerSDL858RNNHigh3+
3Pre-gefitinibLymph nodePDL858RNNHigh3+
Acquired resistancePaired specimens
4Pre-gefitinibPrimary lung cancerPREx19DelNLow3+
Post-gefitinibYNLow1+
5Pre-gefitinibPrimary lung cancerPREx19DelNLow3+
Post-gefitinibYNLow3+
6Pre-gefitinibPrimary lung cancerPREx19DelNLow3+
Post-gefitinibYNLow2+
Posttreatment specimens
7Post-gefitinibLymph nodePRL858RNNHigh3+
8Post-gefitinibLung metastasisPRL858RNNLow2+
Post-gefitinibLung metastasisPRL858RYNLow2+
ResponderPretreatment specimens
9Pre-gefitinibPrimary lung cancerPREx19DelNNELow3+
10Pre-gefitinibLymph nodePRL858RNNLow1+
11Pre-gefitinibPrimary lung cancerPREx19DelNNELow2+
12Pre-gefitinibPrimary lung cancerPREx19DelNNELow1+
13Pre-gefitinibLymph nodePRL858RNNLow3+
14Pre-gefitinibPrimary lung cancerPRL858RNNELow3+
15Pre-gefitinibPrimary lung cancerPRL858RNNELow3+
16Pre-gefitinibLymph nodePREx19DelNNHigh3+
  • Abbreviations: BOR, best overall response to gefitinib treatment; PR, partial response; SD, stable disease; PD, progressive disease; L858R, L858R point mutation in exon 21; Ex19Del, in-frame deletion in exon 19; N, no; Y, yes; NE, not evaluated.